Histogenics set the per-share price range on its forthcoming initial public offering at $13 to $15 per share.
That puts the mid-point for the nearly 4.3 million-share offering at just under $60 million.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Histogenics set the per-share price range on its forthcoming initial public offering at $13 to $15 per share.
That puts the mid-point for the nearly 4.3 million-share offering at just under $60 million.
Nevro Corp. (NYSE:NVRO) today closed its initial public offering, saying it raised $144.9 million by offering 8.05 million shares at $18 apiece.
Lantheus Medical Imaging revived plans for an initial public offering last week, but didn’t set any terms for the flotation.
It’s the 2nd run at the public markets for Billerica, Mass.-based Lantheus, which makes medical imaging isotopes.
Second Sight Medical said today that it plans to raise $31.5 million in an initial public offering, likely next week.
Second Sight created the Argus II "bionic eye," the 1st retinal prosthesis approved for sale by the FDA.
Nevro Corp. today raised the stakes on its forthcoming initial public offering, saying it will offer half a million more shares at a dollar over the high end of its prior range.
Breast implant maker Sientra priced its initial public offering at $15 per share, saying it plans to issue 5 million shares for a total of $75 million.
Sientra, which also has designed implants for the buttocks, calf, pectoral region and face, has backers including Abingworth Bioventures, OrbiMed and Clarus Lifesciences.
Nevro Corp. set the price range for its forthcoming initial public offering, which would raise $106.3 million at the high end of the range.
Menlo Park, Calif.-based Nevro plans to trade on the NASDAQ exchange under the symbol NVRO, according to a regulatory filing.
EndoStim, citing poor market conditions, has tabled its initial public offering it hoped would raise nearly $36 million for its neurostimulation device for gastroesophageal reflux disease, according to Renaissance Capital.
EndoStim had planned to put $10 million of the IPO’s proceeds into clinical studies and another $14 million to commercialize the system.
Breast implant maker Sientra set a price range for its planned initial public offering and raised the upper limit to $92 million, after filing in mid-September for an $86 million IPO.
Histogenics filed for an initial public offering, aiming to raise up to $65 million as it begins Phase III testing of its knee cartilage product NeoCart.
The regenerative medicine company plans to list its shares on the NASDAQ exchange under the symbol HSGX.